Novo Nordisk announces significant outcomes for Mim8 in FRONTIER 2 trial
Novo Nordisk, a global healthcare leader, has announced significant outcomes from the FRONTIER 2 trial, a pivotal phase 3a study, underscoring the effectiveness of its ... Read More